Atyr Pharma Inc (ATYR) concluded trading on Wednesday at a closing price of $5.28, with 4.52 million shares of worth about $23.89 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 41.18% during that period and on July 02, 2025 the price saw a gain of about 2.92%. Currently the company’s common shares owned by public are about 89.00M shares, out of which, 86.06M shares are available for trading.
Stock saw a price change of 3.33% in past 5 days and over the past one month there was a price change of 11.16%. Year-to-date (YTD), ATYR shares are showing a performance of 238.46% which increased to 45.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.48 but also hit the highest price of $5.98 during that period. The average intraday trading volume for Atyr Pharma Inc shares is 2.13 million. The stock is currently trading 0.50% above its 20-day simple moving average (SMA20), while that difference is up 23.64% for SMA50 and it goes to 53.37% higher than SMA200.
Atyr Pharma Inc (NASDAQ: ATYR) currently have 89.00M outstanding shares and institutions hold larger chunk of about 68.51% of that.
The stock has a current market capitalization of $469.94M and its 3Y-monthly beta is at 0.95. It has posted earnings per share of -$0.81 in the same period. It has Quick Ratio of 7.79 while making debt-to-equity ratio of 0.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATYR, volatility over the week remained 8.66% while standing at 8.53% over the month.
Stock’s fiscal year EPS is expected to rise by 28.86% while it is estimated to increase by 0.45% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 18, 2025 offering an Outperform rating for the stock and assigned a target price of $16 to it. On October 04, 2024, Wells Fargo Initiated their recommendations, while on September 05, 2024, Jefferies Initiated their ratings for the stock with a price target of $9. Stock get a Perform rating from Oppenheimer on July 05, 2023.
